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14 Abstract Pituitary adenylate cyclase-activating polypeptide
15 (PACAP), a neuropeptide with trophic and cytoprotective
16 effects, has been shown to affect cell survival, proliferation,
17 and also differentiation of various cell types. The high PACAP
18 level in the milk and its changes during lactation suggest a
19 possible effect of PACAP on the differentiation of mammary
20 epithelial cells. Mammary cell differentiation is regulated by
21 hormones, growth factors, cytokines/chemokines, and angio-
22 genic proteins. In this study, differentiation was hormonally
23 induced by lactogenic hormones in confluent cultures of
24 HC11 mouse mammary epithelial cells. We investigated the
25 effect of PACAP on mammary cell differentiation as well as
26 release of cytokines, chemokines, and growth factors.
27 Differentiation was assessed by expression analysis of the
28 milk protein β-casein. Differentiation significantly decreased
29 the secretion of interferon gamma-induced protein 10 (IP-10),
30 regulated upon activation normal T cell expressed and pre-
31 sumably secreted (RANTES), and the epidermal growth fac-
32 tor receptor (EGFR) ligands epidermal growth factor (EGF)
33 and amphiregulin. The changes in the levels of IP-10 and
34 RANTES may be relevant for the alterations in homing of T
35 cells and B cells at different stages of mammary gland
36development, while the changes of the EGFR ligands may
37facilitate the switch from proliferative to lactating stage.
38PACAP did not modulate the expression of β-casein or the
39activity of hormone-induced pathways as determined by the
40analysis of phosphorylation of Akt, STAT5, and p38 MAPK.
41However, PACAP decreased the release of EGF and
42amphiregulin from non-differentiated cells. This may influ-
43ence the extracellular signal-related transactivation of EGFR
44in the non-differentiated mammary epithelium and is consid-
45ered to have an impact on the modulation of oncogenic EGFR
46signaling in breast cancer.
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49Abbreviations Q2
502ADAM17 3ADAM metallopeptidase domain 17
54AREG 5Amphiregulin
56cAMP 7Cyclic adenosine monophosphate
58CTGF 9Connective tissue growth factor
60EGF 1Epidermal growth factor
62EGFR 3Epidermal growth factor receptor
64FGF 5Fibroblast growth factor
66G-CSF 7Granulocyte colony-stimulating factor
68HGF 9Hepatocyte growth factor
70IGF 1Insulin-like growth factor
72IGFBP 3Insulin-like growth factor-binding protein
74IL 5Interleukin
76IL-1ra 7Interleukin 1 receptor antagonist
78IP-10 9Interferon gamma-induced protein 10
80JAK 1Janus kinase
82M-CSF 3Macrophage colony-stimulating factor
84p38
85MAPK
6p38 Mitogen-activated protein kinases
87PACAP 8Pituitary adenylate cyclase-activating
89polypeptide
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90 PDGF1 Platelet-derived growth factor
92 PKA3 Protein Kinase A
94 PRL5 Prolactin
96 PTHLH7 Parathyroid hormone-like hormone
98 RANK-LQ3 9 Receptor activator of NF-kB ligand
100 RANTES1 Regulated upon activation normal T cell
102 expressed and presumably secreted
103 STAT4 Signal transducer and activator of transcription
105 TIMP6 Tissue inhibitor of metalloproteinase
107 TGF8 Transforming growth factor
109 TNF10 Tumor necrosis factor
111 VEGF2 Vascular endothelial growth factor
113 VIP4 Vasoactive intestinal peptide
115
116 Introduction
117 Pituitary adenylate cyclase-activating polypeptide (PACAP) is
118 a neuropeptide with diverse effects on cell proliferation and
119 differentiation. The developmental effects of PACAP are best
120 known in the central nervous system, where it exerts trophic
121 factor-like effects (Waschek 2002; Watanabe et al. 2007).
122 PACAP appears very early during the development of the
123 nervous system, where it first stimulates proliferation of the
124 cortical and cerebellar neuroblasts, and at a later stage, it
125 influences differentiation, migration, and neuronal patterning
126 (Watanabe et al. 2007). Similar developmental effects have
127 been found in peripheral nervous structures, for example in
128 dorsal root ganglia (Nielsen et al. 2004). PACAP induces
129 differentiation in human neuroblastoma andmouse embryonic
130 stem cells (Cazillis et al. 2004; Monaghan et al. 2008).
131 PACAP has a biphasic, concentration-dependent effect on
132 neuroblastoma cell lines, i.e., it stimulates cell proliferation
133 at subnanomolar concentrations, while at higher doses, it
134 induces differentiation (Vaudry et al. 2009). Less is known
135 about the effects of PACAP on proliferation and differentia-
136 tion of nonneural cells. PACAP inhibits osteoblastic and pre-
137 antral follicle differentiation and is involved in T cell matura-
138 tion (Delgado et al. 1996; Nagata et al. 2009; Latini et al.
139 2010). Some experimental data are available on the effects of
140 PACAP on the growth of tumor cells, like pituitary adenoma,
141 schwannoma, prostatic, colon, and lung carcinoma cells (Zia
142 et al. 1995; Oka et al. 1999; Le et al. 2002; Gutierrez-Canas
143 et al. 2003; Castorina et al. 2008).
144 PACAP is present in certain body fluids, such as human
145 follicular fluid, plasma, and, similarly to vasoactive intestinal
146 peptide (VIP), in the milk (Werner et al. 1985; Borzsei et al.
147 2009; Brubel et al. 2011; Koppan et al. 2012). PACAP-like
148 immunoreactivity is higher in the milk than in the respective
149 plasma samples and it shows significant changes during lac-
150 tation (Borzsei et al. 2009; Csanaky et al. 2012). PACAP-
151 immunoreactive nerve fibers and PACAP receptors have been
152identified in the mammary gland (Skakkebaek et al. 1999;
153Garcia-Fernandez et al. 2004, 2005). These observations raise
154the question about a potential role of PACAP in mammary
155gland development and differentiation.
156It is well known that besides primary estrogen, progester-
157one, and prolactin (PRL), the proliferation and differentiation
158of mammary cells are influenced by cytokines, growth, and
159angiogenic factors (Khaled et al. 2007; Watson et al. 2011).
160PACAP has influence on cytokines, chemokines, and angio-
161genic factors. The expression of vascular endothelial growth
162factor (VEGF), a potent angiogenic factor, is increased by
163binding of PACAP to VPAC1 receptor, and therefore,
164PACAP is assorted as “nonclassic endogenous regulator of
165angiogenesis” (Ribatti et al. 2007). Furthermore, PACAP has
166been shown to be able to modify the cytokine profile by
167decreasing and increasing the production of pro- and certain
168anti-inflammatory cytokines, respectively, as well as
169chemokines and chemokine receptors. PACAP was demon-
170strated to influence cytokine production not only of immuno-
171competent cells (macrophages, lymphocytes), but also of
172other cell types (Nagakawa et al. 2005; Vaudry et al. 2009;
173Horvath et al. 2010).
174In this study, we induced differentiation on HC11 mouse
175mammary cells, which are responsive to lactogenic hormones
176and produce β-casein “in vitro” (Ball et al. 1988). We inves-
177tigated whether PACAP has any effect on this differentiation
178process. Moreover, PRL- and/or PACAP-induced changes in
179secreted cytokines, growth, and angiogenic factors were in-
180vestigated with mouse cytokine and angiogenesis arrays. The
181observed effects are discussed in light of the current literature
182on the role of these regulatory factors on growth and differ-
183entiation of mammary epithelial cells.
184Materials and Methods
185Reagents and Antibodies
186Bovine insulin, ovine prolactin, and dexamethasone were
187purchased from Sigma (St. Louis, MO). Recombinant murine
188epidermal growth factor (EGF) was obtained from Peprotech
189(Rocky Hill, NJ). Primary antibodies were applied as it fol-
190lows: antiphospho-Akt (Thr308; Cell Signaling Technology,
191Beverly, MA) at 1:500; anti Akt-1 (C20; Santa Cruz
192Biotechnologies) at 1:500; antiphospho-p38 MAP kinase
193(Thr180/Tyr182; Cell Signaling Technology) at 1:1,000;
194anti-p38 MAP kinase (Cell Signaling Technology) at
1951:1,000; antiphospho-signal transducer and activator of tran-
196scription (STAT)-5 (Tyr694, recognizes also Tyr699 of
197STAT5B; Cell Signaling Technology) at 1:900; anti-STAT5
198(Cell Signaling Technology) at 1:900; anti-α-tubulin (Santa
199Cruz Biotechnologies) at 1:1,000; and anti-β-casein (M-14;
200Santa Cruz Biotechnologies) at 1:1,000. Corresponding anti
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201 IgG-horseradish peroxidase (Q4 HRP) secondary antibodies were
202 purchased from Santa Cruz Biotechnologies. PACAP38 was
203 synthesized using a solid-phase procedure utilizing tBoc
204 chemistry (Pirger et al. 2010).
205 Cell Culture and Hormone Induction
206 HC11 mouse mammary epithelial cells were maintained in
207 growth medium, which contained RPMI-1640, 10 % heat-
208 activated fetal calf serum (FCS), 5 μg/ml insulin (I), and
209 10 ng/ml EGF supplemented with 50 μg/ml gentamicin and
210 glutamine. Cells were grown in 5 % CO2 at 37 °C and
211 passaged every 3–4 days. Cells were plated in six-well plates
212 and grown to confluence for 2–3 days. After the cells reached
213 the confluent state, they were washed twice with PBS to
214 remove EGF, and an additional 2-day incubation was carried
215 out in pre-hormone medium (PHM) containing RPMI-1640,
216 2 % FCS, 5 μg/ml insulin, and 50 μg/ml gentamicin and
217 glutamine.Q5 After 2 days, the medium was changed to DIP
218 medium containing 1 μM dexamethasone (D), 5 μg/ml I, and
219 5 μg/ml prolactin (P) in PHM. The PHMwas changed, and D,
220 PRL, and PACAP38 were added to the cell cultures every day
221 (Fig. 1). The cell cultures were co-incubated with 100 nM
222 PACAP38 for 4 days with and without PRL in cell differen-
223 tiation experiments. In signal transduction experiments,
224 Western blot analysis was performed on confluent cell cul-
225 tures after 20 min of DIP and 100 nM PACAP38 treatment.
226 Western Blot Analysis
227 Cell lysates were prepared by washing cells three times with
228 ice-cold PBS followed by lysis for 30 min at 4 °C in lysis
229 buffer (50 mM HEPES (pH 7.5), 150 mM NaCl, 1 mM
230 EGTA, 2 mM EDTA, 25 mM β-glycerophosphate, 1.5 mM
231 MgCl2, 10 % glycerol, 1 % Triton X-100, 5 μg/ml aprotinin,
232 5 μg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride,
233 1 mM dithiothreitol, 1.19 mM Na3VO4, and 2.5 mM NaF).
234 Lysates were centrifuged (15,300 rpm) at 4 °C for 10 min to
235 remove insoluble parts. Protein concentration was determined
236 by Bradford, and proteins were separated by SDS-PAGE and
237 blotted on Odyssey membranes. Membranes were blocked
238with 5 % milk for 30 min at room temperature, incubated
239overnight at 4 °C with the primary antibodies, and then further
240incubated for 30 min at room temperature with the appropriate
241secondary antibodies and the reactions were detected with the
242ECL Plus Western blotting detection system (GE Healthcare,
243Little Chalfont, UK).
244Mouse Cytokine Array and Mouse Angiogenesis Array
245Secreted cytokines and angiogenesis-related proteins were
246investigated by semiquantitative Mouse Cytokine Array
247Panel A and Mouse Angiogenesis Array Kit (R&D Systems,
248Hungary). In these arrays, the investigated proteins bind care-
249fully selected captured antibodies spotted in duplicate on
250nitrocellulose membranes. The kits contain all buffers, detec-
251tion antibodies, and membranes necessary for the measure-
252ments. The arrays were performed as described by the manu-
253facturer. Briefly, after blocking the array membranes for 1 h,
254500 μl medium was added and incubated overnight at 2–8 °C
255on a rocking platform with detection antibody cocktail. After
256washing with buffer three times and adding HRP-conjugated
257streptavidin, the membranes were exposed to chemilumines-
258cent detection reagent. X-ray films were scanned on transmis-
259sion mode. Factors which showed changes with eye control in
260each experiment were analyzed by ImageJ software. The
261positive controls at the reference spots were normalized to
262non-differentiated cells in order to compare the results from
263different membranes. Pixel densities were expressed in arbi-
264trary units. The released proteins of stimulated cells were
265compared to that of the non-differentiated untreated cells.
266Statistical analysis was performed by one- and two-way
267ANOVA test.
268Results
269β-casein was expressed in HC11 cells only after DIP treat-
270ment, as described previously (Ball et al. 1988). PACAP co-
271incubation without PRL did not induce β-casein expression,
272and it did not modify the DIP-evoked β-casein expression
273either (Fig. 2). The downstream signaling via phosphorylation
Fig. 1 TimelineQ6 of the experiment. GM growth medium, PHM pre-hormone medium
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274 of STAT5 was activated by PRL as reported previously (Welte
275 et al. 1994). Akt/p38 mitogen-activated protein kinase (p38
276 MAPK) phosphorylation, which can be triggered by insulin in
277 these cells (Berlato and Doppler 2009), was observed under
278 all experimental conditions. No modulating effect of PACAP
279 on STAT5, Akt, or p38 MAPK was detectable (Fig. 3).
280 The mouse cytokine array measurements showed that dif-
281 ferentiated HC11 cells secreted significantly lower levels of
282 interferon gamma-induced protein 10 (IP-10) and regulated
283 upon activation normal T cell expressed and presumably
284 secreted (RANTES) compared to the non-differentiated cells.
285 A further decrease was observed in secretion of RANTES
286 after PACAP co-incubation of differentiated cells, but this
287 change did not prove to be statistically significant. In differ-
288 entiated cells, a consequent increase of released I-309 and
289 interleukin 1 receptor antagonist (IL-1ra) and a decrease of
290 macrophage colony-stimulating factor (M-CSF) were pre-
291 sumed by eye control, but these changes were not significant
292 by densitometric analysis. The interleukin (IL) series showed
293 very weak densities and they were not analyzed further
294 (Figs. 4 and 5).
295 On the angiogenesis array, the IGFBP10 signal was well
296 detectable, but did not show changes in intensity after DIP
297 or PACAP treatment, while other insulin-like growth
298factor-binding proteins (IGFBPs), such as IGFBP1, 2, and 9,
299did not produce signals at all (Fig. 6). The media of differen-
300tiated cells showed a significant drop of EGF, amphiregulin
301(AREG), and IGFBP3 on the angiogenesis array (Fig. 6,
302compare encircled spots in panels A and C). PACAP co-
303incubation significantly decreased the expression of EGF
304and AREG in non-differentiated cells (Fig. 6b), while there
305were no changes in these factors in differentiated cells
306(Fig. 6d). Quantification of differentiation and PACAP-
307induced changes of EGF, AREG, and IGFBP3 is shown in
308Fig. 7. Neither hepatocyte growth factor (HGF) nor “classic”
309angiogenic factors, such as VEGF, fibroblast growth factor
310(FGF)-2, angiopoietin, and thrombospondin, produced signals
311suitable for densitometric analysis. PDGF-AA did not show
312changes under eye control after DIP or PACAP co-treatment.
313Inconsequent or weak signals were seen in connection with
314other proteins (Fig. 6).
315Discussion
316Three major stages of mammary gland development can
317be distinguished, namely ductal elongation/bifurcation in
318puberty, side branching in estrous cycles, and alveologenesis/
Fig. 2Q7 Western blot analysis of β-
casein expression in HC11 cells in
the presence and absence of
PACAP. Two different HC11 cell
clones were investigated. a A23
clone (one to three bands): 1 DIP;
2 DIP+PACAP; 3 DI+PACAP;
B22 clone (four to six bands):
4 DIP; 5 DIP+PACAP; 6 DI+
PACAP. DIP induces β-casein
expression (1 and 4). The band of
β-casein does not appear after
PACAP treatment without PRL
(3 and 6), and PACAP has no
modulatory effect on DIP-
induced β-casein expression
either (2 and 5). b Densitometric
analysis of three independent
experiments on B22 clone.
Results are shown mean ± SE,
and α-tubulin serves as control
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319 lactogenic differentiation in pregnancy (Brisken and
320 O’Malley 2010). Lactogenic differentiation of mammary ep-
321 ithelial cells mainly requires hormonal signaling. Binding of
322 PRL to its receptor induces homodimerization resulting in
323 JAK2/STAT5 activation. The STAT5 dimer translocates to
324 the nucleus and promotes transcription of β-casein.
325 Besides hormones, cytokines/chemokines and growth fac-
326 tors modulate lactogenic differentiation. IL-4/IL13/STAT6
327 signaling is an important regulator of alveologenesis. This
328 pathway is also associated with differentiation of naive T
329 helper cells (Khaled et al. 2007; Watson et al. 2011). The
330 tumor necrosis factor (TNF) family molecule, RANK-L, and
331 its receptor are also implicated in terminal differentiation (Kim
332 et al. 2002). TNFα stimulates mammary differentiation
333 in vitro, but only in the absence or upon deficiency of EGF
334 (Ip et al. 1992). Furthermore, connective tissue growth factor
335 (CTGF) enhances β-casein transcription, while siRNA-
336 mediated depletion of CTGF blocks differentiation showing
337 that even growth factors intervene with the process of lacto-
338 genic differentiation (Morrison et al. 2010).
339 HC11 cells are derived frommid-pregnant BALB/c mouse.
340 This cell line serves as a model to investigate the molecular
341 mechanism of hormones, cytokines, growth, and transcrip-
342 tional factors involved in differentiation (Ball et al. 1988;
343 Doppler et al. 1989). Confluent HC11 cells are responsive to
344 lactogenic hormones resulting in terminal differentiation and
345 expression of milk proteins as it was proven by the induction
346of β-casein gene expression in our study. We extended the
347characterization of lactogenic hormone-induced differentia-
348tion by determining secretion of almost 50 chemokines/
349cytokines, several growth/angiogenesis-related proteins, and
350some other factors with the mouse cytokine array panel and
351angiogenesis kits.
352A significant decrease of IP-10 and RANTES was mea-
353sured in the cell culture media of differentiated HC11 cells. IP-
35410 and RANTES are chemokines, responsible for the recruit-
355ment of T lymphocytes and some other leukocytes (Schall
356et al. 1990; Angiolillo et al. 1995). They are present in the
357mammary gland and milk, and they are supposed to maintain
358the balance of lymphocyte homing to the mammary gland at
359different stages of differentiation (Michie et al. 1998; Takahata
360et al. 2003). Colonization of mammary gland is dominated by
361T cells during pregnancy, while Ig-A containing B cells are
362abundant during lactation (Tanneau et al. 1999). Therefore,
363decreased release of T cell attractants, such as IP-10 and
364RANTES in our experiment, may reflect the shift of T to B
365cells in lactating glands.
366Khaled et al. applied a similar cytokine assay on the media
367of non-differentiated and 8-day differentiated KIM-2 mouse
368mammary epithelial cells, and they observed that the secretion
369of IL-4 was higher in the differentiated cells, while the secre-
370tion of granulocyte colony-stimulating factor (G-CSF) and IL-
3716 decreased. Other Th2 cytokines (IL-2, IL-3, IL-5, IL-9, IL-
37210, and IL-13) did not show changes in their study. Moreover,
373with the use of qRT-PCR, they observed a Th1/Th2 cytokine
374switch in the expression profile concomitant with induction of
375differentiation, i.e., IL-12 and TNFα were downregulated,
376while IL-4, IL-5, and IL-13 were upregulated (Khaled et al.
3772007). We could not detect similar changes in the release of
378IL-4, IL-6, and G-CSF from differentiated HC11 cells and this
379may reflect cell line-specific differences as well as the differ-
380ent differentiation protocol used in our study.
381In our experiment, IGFBP3 was abundantly present in the
382media of non-differentiated HC11 cells, while decreased
383levels of IGFBP3 were measured after DIP treatment.
384Similarly, Skaar et al. demonstrated decreased IGFBP3 secre-
385tion of Comma-1D cells, a progenitor of HC11 cell line after
386treatment with dexamethasone (Skaar and Baumrucker 1993).
387IGFBPs are carrier proteins and they modulate the activity of
388insulin-like growth factors (IGFs). Decreased in vitro IGFBP3
389secretion of differentiated HC11 cells is compatible with the
390physiological decrease of IGFBPs during lactation allowing
391maximal effect of IGFs, which are recognized as endocrine
392and paracrine modulators of PRL-induced alveolar differenti-
393ation (Allar and Wood 2004).
394The decreased AREG and EGF release from differentiated
395HC11 cells may reflect the switch from proliferative to lacto-
396genic phase. Expression of AREG transcripts has been shown
397to be regulated by PRL (Ormandy et al. 2003), but, to our
398knowledge, no data are available about the effect of PRL on
Fig. 3 Western blot analysis of p38 MAPK, STAT5, and Akt in extracts
of HC11 cells. 1 DIP; 2 DIP+PACAP; 3 DI+PACAP; 4 I+PACAP; 5 I.
The abundance of phosphorylated activated forms of p38MAPK and Akt
remained similar under all experimental conditions investigated, and thus,
it did not appear to be significantly influenced by PRL, dexamethasone,
and PACAP, while STAT5 was phosphorylated only in the presence of
PRL. There was no change in STAT5 activation in case of PACAP co-
incubation (similar bands in 1–2). Without PRL, PACAP could not
activate STAT5 (lack of pSTAT5 in 3–5)
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399 their secretion. Production of AREG is induced by estrogen in
400 peripubertal breasts, and it is downregulated during and after
401 pregnancy. Once expressed, AREG exists as a membrane-
402 associated precursor. AREG released frommammary epithelium
403 binds to epidermal growth factor receptor (EGFR) of stromal
404 cells, and this has been shown to be important for the expression
405 of growth factors (FGF, HGF, IGF1), which are implicated in
406 stimulating the proliferation of other epithelial cells (McBryan
407 et al. 2008). AREG, EGF, and transforming growth factor
408 (TGF)α are structurally related proteins. While AREG is
409specifically required for ductal morphogenesis, EGF and
410TGFα are dispensable for this process (Luetteke et al. 1999).
411EGF blocks functional differentiation (β-casein and WAP
412production) or results in dedifferentiation (Spitzer et al. 1995).
413The regulatory role of neuropeptides outside the nervous
414and endocrine system is widely accepted, e.g., neuronal pep-
415tide galanin not only regulates PRL secretion from the pitui-
416tary lactotrophs, but the mammary epithelium is also directly
417responsive to galanin, as it augments alveolar morphogenesis
418(Naylor et al. 2003). In our study, PACAP had no influence on
Fig. 4 Mouse cytokine array panel a of non-differentiated (a , b) and
differentiated HC11 cells (c , d) without PACAP (a , c) and with PACAP
co-incubation (b , d). Proteins which show obvious changes in expression
after DIP and/or PACAP treatment are marked by circles and comprise
B5 = I-309; B11 = IL-1ra; D1 = IP-10; D4 = M-CSF; and D11 =
RANTES
Fig. 5 Image analysis of some
secreted cytokines. Secreted IP-10
and RANTES are significantly
lower in culture media of
differentiated cells compared to
non-differentiated ones (*p<0.05;
**p<0.005). The different arrays
are normalized to the controls of
non-differentiated cells, and the
bar charts show the relative
changes in protein expressions
based on three independent
measurements
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419 the differentiation of HC11 cells either at the level of β-casein
420 production or phosphorylation of proteins involved in lacto-
421 genic hormone signaling.
422 The observed PACAP-induced decrease of secreted AREG
423 and EGF from non-differentiated HC11 cells may be a conse-
424 quence of (a) decreased ligand shedding and/or (b) decreased
425 expression of these EGFR ligands. A possible mechanism for
426 decreased EGFR ligand shedding could be the reported
427dependence of TGF-β expression on PACAP, as evident from
428TGF-β downregulation in PACAP KO mice (Tan et al. 2009),
429and the role of TGF-β in inhibition of ADAMmetallopeptidase
430domain 17 (ADAM17), a metalloproteinase implicated in shed-
431ding of AREG, EGF, TGF-α, and activation of EGFR
432(Sternlicht et al. 2005). TGF-β downregulates matrix degrading
433proteinases, including ADAM17, and upregulates their inhibi-
434tors, such as TIMP-3 (Leivonen et al. 2013; Wada et al. 2013).
Fig. 6 Mouse angiogenesis array of non-differentiated (a , b) and differ-
entiated HC11 cells (c , d) without PACAP (a , c) and with PACAP co-
incubation (b , d). Proteins which show obvious changes after DIP and/or
PACAP treatment are indicated by circles and comprise A4 = AREG,
B5 = EGF, and C9 = IGFBP3
Fig. 7 Image analysis of AREG,
EGF, and IGFBP3. Differentiation
resulted in significantly decreased
levels in all of these growth
factors, while PACAP treatment
decreased the level of AREG and
EGF in non-differentiated cells
(*p<0.05; ***p<0.001). All
measurements were repeated three
times. The different arrays were
normalized to the controls of
non-differentiated cells
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435 Whether TGF-β is expressed in HC11 cells and modified by
436 PACAP remains to be shown in further studies.
437 In contrast to our findings with non-differentiated mammary
438 epithelial cells, where PACAP inhibited expression of growth
439 factors, PACAP has a growth factor-like activity on neural cells
440 (Grumolato et al. 2003; Somogyvári-Vigh and Reglodi 2004;
441 Vaudry et al. 2009). PACAP/PAC1-R interaction via cAMP/
442 PKA signaling-stimulated Src-ADAM17 increased TGF-α re-
443 lease and transactivated EGFR on lung carcinoma cells.
444 Administration of anti-AREG did not reverse the PACAP-
445 induced transactivation of EGFR (Moody et al. 2012).
446 Likewise, VIP transactivated EGFR and inducedVEGF release
447 on mammary carcinoma cells (Valdehita et al. 2008).
448 Our results on the PACAP-mediated downregulation of
449 AREG and EGF may also have significance in light of some
450 experimental oncology data. AREG is a crucial growth factor
451 influencing the proliferation of mammary epithelial tumor
452 cells, and EGFR transactivation-dependent breast cancers uti-
453 lize ADAM-mediated EGFR ligand shedding. Therefore,
454 AREG is a promising target for drug intervention (Moody
455 et al. 2012). Interestingly, AREG is supposed to contribute
456 even to bone metastasis by stimulation of bone resorption via
457 autocrine AREG-EGFR signaling to promote PTHLH pro-
458 duction (Q8 Gilmore et al. 2008).
459 In summary, we demonstrated that PACAP had no direct
460 effect on the lactogenic hormone-induced terminal differenti-
461 ation of HC11 mouse mammary epithelial cells. A significant
462 decrease in the release of IP-10/RANTESwas detected during
463 differentiation which might be relevant for influencing the
464 altered recruitment of lymphocytes in the terminal differenti-
465 ated gland as it is observed under “in vivo” conditions. The
466 decreased secretion of AREG/EGF is considered to contribute
467 to the proliferative to lactogenic phase switch in terminal
468 differentiated gland. Interestingly, PACAP co-incubation sig-
469 nificantly decreased the levels of AREG and EGF secreted
470 from non-differentiated mammary cells, which may have
471 physiological implications. Furthermore, in the light of the
472 prominent role of EGFR signaling in breast cancer, this inhib-
473 itory effect of PACAP could be relevant in influencing the
474 development and progression of this disease.
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